Environmental Determinants, Multi-Omics Integrative Biology, and Precision Medicine for Obesity, Chronic Inflammatory Bowel Diseases, and Cancer
L’équipe 2 de l’UMRS INSERM U1256 N-GERE est dirigée par le Dr Catherine MALAPLATE et s’articule autour de 3 axes de recherche.
The 3 Research Areas of the Team
Group 1: Environment, Integrative Biology and Precision Medicine in Obesity and Its Comorbidities
Lead: Prof. Thierry OSTER
Obesity and its associated comorbidities result from complex interactions between environmental factors (unhealthy diet, physical inactivity, stress, pollution) and biological determinants, including sex, age, hormonal changes (such as puberty, pregnancy, menopause, and andropause), gut microbiota, fetal programming, epigenetics, and genetics.
Our primary objective is to elucidate the determinants of obesity and its comorbidities and to accelerate the transition from conventional medicine to precision medicine for obesity, both in France and worldwide. This research program focuses on four major obesity subtypes: environmental obesity, developmental obesity, monogenic obesity, and polygenic obesity.
Group 2: Integrative and Targeted Approaches in Inflammatory Bowel Diseases (IBD)
Lead: Dr. Djésia ARNONE
Our objective is to investigate the pathophysiology of inflammatory bowel diseases (IBD) through a translational research approach aimed at characterizing the impact of the exposome on the molecular and cellular mechanisms underlying these disorders.
The team also develops innovative therapeutic strategies and non-invasive monitoring tools through numerous local, national, and international collaborations. This research is fully aligned with the scientific program of the IHU INFINY, contributing to both fundamental and translational research in the field of IBD.
Group 3: Multi-Omics and Predictive Biomarkers in Cancer
Leads: Prof. Julien BROSÉUS and Prof. Guillaume GAUCHOTTE
Our objective is to investigate the biological mechanisms underlying tumor initiation, progression, and therapeutic resistance in order to identify novel therapeutic targets in indolent and transformed B-cell lymphomas, central nervous system tumors, lung cancers, and olfactory cleft cancers.
To achieve this, we develop integrative multi-omics approaches and dedicated bioinformatics tools for cancer genomics, enabling a deeper understanding of tumor biology and facilitating the discovery of predictive biomarkers and personalized therapeutic strategies.
